检索结果 - Sang‐Won Shin
- Showing 1 - 13 results of 13
-
1
-
2
-
3
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer 由 Dong‐Wook Kim, Sun‐Young Kim, H.-K. Kim, S.-W. Kim, Sang Won Shin, Kim Js, K. Park, M. Y. Lee, D. S. Heo
出版 2007Artigo -
4
-
5
-
6
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy 由 Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong Seok Lee, Sang Won Shin, Jin Hyoung Kang, Myung‐Ju Ahn, Jin Seok Ahn, Cheolwon Suh, Sang-We Kim
出版 2010Artigo -
7
-
8
Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis 由 Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu
出版 2023Artigo -
9
Data from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Ampl... 由 Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu
出版 2023Pré-impressão -
10
Data from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Ampl... 由 Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu
出版 2023Pré-impressão -
11
Data from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Ampl... 由 Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu
出版 2023Pré-impressão -
12
Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer 由 Joon Oh Park, Sang‐We Kim, Jin Seok Ahn, Cheolwon Suh, Jung Shin Lee, Joung Soon Jang, Eun Kyung Cho, Sung Hyun Yang, Jin-Hyuk Choi, Dae Seog Heo, Suk Young Park, Sang Won Shin, Myung‐Ju Ahn, Jong Seok Lee, Young Ho Yun, Jae‐Won Lee, Keunchil Park
出版 2007Artigo -
13
A pharmacoinformatic approach for studying Atractylodes Lancea DC’s anticancer potential and control ROS-mediated apoptosis against prostate cancer cells 由 Chi‐Hoon Ahn, Ji Soo Myong, Kazi Rejvee Ahmed, Md. Ataur Rahman, Md. Maharub Hossain Fahim, Min Ji Choi, M M Rahman, Jinwon Choi, K W Kim, Seungjoon Moon, Mohammed Dalli, Rony Abdi Syahputra, Sang‐Won Shin, Abdel Halim Harrath, Moon Nyeo Park, Bonglee Kim, Hwa‐Seung Yoo
出版 2025Artigo
相关主题
Medicine
Internal medicine
Oncology
Chemotherapy
Cancer
Epidermal growth factor receptor
Gefitinib
Randomized controlled trial
Clinical endpoint
Biology
Gastroenterology
Lung cancer
Biochemistry
Cisplatin
Paclitaxel
Surgery
Toxicity
Angiogenesis
Angiotensin II
Angiotensin receptor
Angiotensin-converting enzyme
Apoptosis
Blood pressure
Cancer research
Carcinoma
Catalysis
Compound heterozygosity
Demography
Denaturing high performance liquid chromatography
Docetaxel